What are the standard dosing regimens for imipenem‑cilastatin, aztreonam, and ertapenem in adults, including adjustments for renal impairment?

Standard Dosing for Imipenem-Cilastatin, Aztreonam, and Ertapenem

Imipenem-Cilastatin

For adults with normal renal function, administer imipenem-cilastatin 500 mg every 6 hours or 1 g every 8 hours intravenously 1. The maximum daily dose should not exceed 4 g/day or 50 mg/kg/day, whichever is lower 2.

Dosing in Renal Impairment

Renal function critically determines imipenem clearance, requiring dose adjustments to prevent both subtherapeutic levels and neurotoxicity 3:

• CrCl 41-70 mL/min: 500 mg every 8 hours
• CrCl 21-40 mL/min: 500 mg every 12 hours
• CrCl 6-20 mL/min: 250-500 mg every 12 hours
• Hemodialysis patients: 500 mg every 12 hours, administered after dialysis sessions 4, 5

The key principle is maintaining therapeutic trough levels (>4 mg/L) for 8-10 hours while avoiding excessive peak concentrations that increase seizure risk 6. For severe infections in renal impairment, consider prolonging infusion time to 1.5 hours rather than reducing dose, as this maintains higher PK/PD breakpoints 7.

Pediatric Dosing

For children beyond the neonatal period: 60-100 mg/kg/day divided every 6 hours IV (maximum 4 g/day) 1. The British Thoracic Society recommends 20-40 mg/kg three times daily for children with NTM infections 3.

---

Aztreonam

For adults with normal renal function, administer aztreonam 1-2 g every 6-8 hours intravenously 1. For serious infections, particularly those involving Pseudomonas aeruginosa, use the higher dose of 2 g every 6-8 hours.

Dosing in Renal Impairment

Aztreonam requires dose adjustment in renal dysfunction 4:

• CrCl >30 mL/min: Standard dosing (1-2 g every 6-8 hours)
• CrCl ≤30 mL/min or hemodialysis: 25-35 mg/kg per dose three times weekly (not daily)
• Administer after hemodialysis on dialysis days to avoid premature drug removal 4

Monte Carlo simulations support that these adjusted regimens achieve >90% probability of target attainment for organisms with MIC ≤4-8 mg/L in patients with moderate to severe renal impairment 8.

Pediatric Dosing

For children: 90-120 mg/kg/day divided every 6-8 hours IV (maximum dose per guidelines) 1.

---

Ertapenem

For adults with normal renal function, administer ertapenem 1 g once daily intravenously 1. This once-daily dosing is a key advantage over other carbapenems.

Dosing in Renal Impairment

• CrCl >30 mL/min: 1 g once daily (no adjustment needed)
• CrCl ≤30 mL/min or hemodialysis: Reduce to 500 mg once daily 9
• For hemodialysis patients: Administer the daily dose after dialysis 4

Pediatric Dosing

• Ages 3 months to 12 years: 15 mg/kg twice daily (maximum 1 g/day) 1
• Ages ≥13 years: 1 g once daily 1

---

Critical Clinical Considerations

Common Pitfalls to Avoid

1. Failing to adjust for renal function: All three agents require dose modification in renal impairment. Use Cockcroft-Gault equation for medication dosing adjustments, not MDRD or CKD-EPI 10.

2. Timing with hemodialysis: Always administer these antibiotics after hemodialysis to prevent premature drug removal and facilitate directly observed therapy 4.

3. Ignoring residual renal function: Patients on dialysis may have significant residual renal clearance that contributes to drug elimination, potentially requiring higher doses than anticipated 11.

4. Seizure risk with imipenem: Particularly concerning in patients with CNS disorders, renal impairment, or concurrent valproic acid use. Consider meropenem as alternative if seizure risk is high 2.

Therapeutic Drug Monitoring

For imipenem in critically ill patients or those with renal impairment, measure trough concentrations 24-48 hours after treatment initiation 11. Target: maintain free drug concentrations above the MIC for 40-100% of the dosing interval depending on infection severity 12.

Drug Interactions

• Imipenem + valproic acid: Avoid this combination as imipenem significantly reduces valproate levels, increasing seizure risk 2
• Imipenem + ganciclovir: Increased seizure risk; avoid concurrent use 3
• All agents + probenecid: Prolongs elimination; avoid combination 2